Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.

Jeong J, Jager A, Domizi P, Pavel-Dinu M, Gojenola L, Iwasaki M, Wei MC, Pan F, Zehnder JL, Porteus MH, Davis KL, Cleary ML.

Blood Adv. 2019 Oct 8;3(19):2825-2835. doi: 10.1182/bloodadvances.2019000450.

2.

Oligomeric self-association contributes to E2A-PBX1-mediated oncogenesis.

Lin CH, Wang Z, Duque-Afonso J, Wong SH, Demeter J, Loktev AV, Somervaille TCP, Jackson PK, Cleary ML.

Sci Rep. 2019 Mar 20;9(1):4915. doi: 10.1038/s41598-019-41393-w.

3.

Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia.

Becker H, Greve G, Kataoka K, Mallm JP, Duque-Afonso J, Ma T, Niemöller C, Pantic M, Duyster J, Cleary ML, Schüler J, Rippe K, Ogawa S, Lübbert M.

Blood Adv. 2019 Mar 12;3(5):761-765. doi: 10.1182/bloodadvances.2018023879. No abstract available.

4.

MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation.

Crisafulli L, Muggeo S, Uva P, Wang Y, Iwasaki M, Locatelli S, Anselmo A, Colombo FS, Carlo-Stella C, Cleary ML, Villa A, Gentner B, Ficara F.

Haematologica. 2019 Sep;104(9):1744-1755. doi: 10.3324/haematol.2018.198499. Epub 2019 Feb 21.

5.

CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia.

Duque-Afonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SHK, Zhu L, Wei MC, Chae HD, Schrappe M, Cario G, Duyster J, Xiao X, Sakamoto KM, Bassik MC, Cleary ML.

Cancer Res. 2018 Nov 15;78(22):6497-6508. doi: 10.1158/0008-5472.CAN-18-1703. Epub 2018 Sep 27.

6.

SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.

Lin CH, Wong SH, Kurzer JH, Schneidawind C, Wei MC, Duque-Afonso J, Jeong J, Feng X, Cleary ML.

Cell Rep. 2018 Apr 24;23(4):1166-1177. doi: 10.1016/j.celrep.2018.03.124.

7.

MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing.

Schneidawind C, Jeong J, Schneidawind D, Kim IS, Duque-Afonso J, Wong SHK, Iwasaki M, Breese EH, Zehnder JL, Porteus M, Cleary ML.

Blood Adv. 2018 Apr 24;2(8):832-845. doi: 10.1182/bloodadvances.2017013748.

8.

E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.

Duque-Afonso J, Lin CH, Han K, Wei MC, Feng J, Kurzer JH, Schneidawind C, Wong SH, Bassik MC, Cleary ML.

Cancer Res. 2016 Dec 1;76(23):6937-6949. Epub 2016 Oct 7.

9.

Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses.

Fidanza M, Seif AE, DeMicco A, Rolf N, Jo S, Yin B, Li Y, Barrett DM, Duque-Afonso J, Cleary ML, Bassing CH, Grupp SA, Reid GS.

Leukemia. 2016 Oct;30(10):2116-2119. doi: 10.1038/leu.2016.152. Epub 2016 May 25. No abstract available.

10.

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.

Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Martin GM, Gozani O, Majeti R, Kutateladze TG, Cleary ML.

Cancer Discov. 2016 Jul;6(7):770-83. doi: 10.1158/2159-8290.CD-16-0058. Epub 2016 May 6.

11.

Conditional Expression of E2A-HLF Induces B-Cell Precursor Death and Myeloproliferative-Like Disease in Knock-In Mice.

Duque-Afonso J, Smith KS, Cleary ML.

PLoS One. 2015 Nov 20;10(11):e0143216. doi: 10.1371/journal.pone.0143216. eCollection 2015.

12.

CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Iwasaki M, Liedtke M, Gentles AJ, Cleary ML.

Cell Stem Cell. 2015 Oct 1;17(4):412-21. doi: 10.1016/j.stem.2015.08.008. Epub 2015 Sep 18.

13.

Use of Genome Engineering to Create Patient Specific MLL Translocations in Primary Human Hematopoietic Stem and Progenitor Cells.

Breese EH, Buechele C, Dawson C, Cleary ML, Porteus MH.

PLoS One. 2015 Sep 9;10(9):e0136644. doi: 10.1371/journal.pone.0136644. eCollection 2015.

14.

MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Buechele C, Breese EH, Schneidawind D, Lin CH, Jeong J, Duque-Afonso J, Wong SH, Smith KS, Negrin RS, Porteus M, Cleary ML.

Blood. 2015 Oct 1;126(14):1683-94. doi: 10.1182/blood-2015-05-646398. Epub 2015 Aug 26.

15.

Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.

Duque-Afonso J, Feng J, Scherer F, Lin CH, Wong SH, Wang Z, Iwasaki M, Cleary ML.

J Clin Invest. 2015 Sep;125(9):3667-80. doi: 10.1172/JCI81158. Epub 2015 Aug 24.

16.

The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.

Wong SH, Goode DL, Iwasaki M, Wei MC, Kuo HP, Zhu L, Schneidawind D, Duque-Afonso J, Weng Z, Cleary ML.

Cancer Cell. 2015 Aug 10;28(2):198-209. doi: 10.1016/j.ccell.2015.06.003. Epub 2015 Jul 16.

17.

Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.

Aikawa Y, Yamagata K, Katsumoto T, Shima Y, Shino M, Stanley ER, Cleary ML, Akashi K, Tenen DG, Kitabayashi I.

Cancer Sci. 2015 Mar;106(3):227-36. doi: 10.1111/cas.12593. Epub 2015 Feb 12.

18.

Novel methods and approaches to acute lymphoblastic leukemia drug discovery.

Wei MC, Cleary ML.

Expert Opin Drug Discov. 2014 Dec;9(12):1435-46. doi: 10.1517/17460441.2014.956720. Epub 2014 Sep 12. Review.

PMID:
25212992
19.

The AML salad bowl.

Duque-Afonso J, Cleary ML.

Cancer Cell. 2014 Mar 17;25(3):265-7. doi: 10.1016/j.ccr.2014.03.002.

20.

Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.

Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M, Piloto O, Solow-Cordero DE, Bouley DM, Rau R, Brown P, McManus MT, Weissman JS, Cleary ML.

Chem Biol. 2013 Nov 21;20(11):1352-63. doi: 10.1016/j.chembiol.2013.09.014. Epub 2013 Oct 31.

21.

Epigenetic roles of MLL oncoproteins are dependent on NF-κB.

Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SH, Lin CH, Figueroa ME, Su J, Lemischka IR, Cleary ML.

Cancer Cell. 2013 Oct 14;24(4):423-37. doi: 10.1016/j.ccr.2013.08.019. Epub 2013 Sep 19.

22.

MLL becomes functional through intra-molecular interaction not by proteolytic processing.

Yokoyama A, Ficara F, Murphy MJ, Meisel C, Hatanaka C, Kitabayashi I, Cleary ML.

PLoS One. 2013 Sep 10;8(9):e73649. doi: 10.1371/journal.pone.0073649. eCollection 2013.

23.

Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors.

Ficara F, Crisafulli L, Lin C, Iwasaki M, Smith KS, Zammataro L, Cleary ML.

J Cell Sci. 2013 Jul 15;126(Pt 14):3181-91. doi: 10.1242/jcs.125435. Epub 2013 May 9.

24.

Developing and using multiple-choice tests in clinical settings.

Cleary ML, Horsfall J.

J Contin Educ Nurs. 2012 Aug;43(8):344-5. doi: 10.3928/00220124-20120725-04.

PMID:
22849628
25.

Genomics: The path to retinoblastoma.

Sage J, Cleary ML.

Nature. 2012 Jan 18;481(7381):269-70. doi: 10.1038/481269a. No abstract available.

26.

PBX1: a novel stage-specific regulator of adipocyte development.

Monteiro MC, Sanyal M, Cleary ML, Sengenès C, Bouloumié A, Dani C, Billon N.

Stem Cells. 2011 Nov;29(11):1837-48. doi: 10.1002/stem.737. Erratum in: Stem Cells. 2012 Mar;30(3):585. Bouloumé, Anne [corrected to Bouloumié, Anne].

27.

Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex.

Heuser M, Yun H, Berg T, Yung E, Argiropoulos B, Kuchenbauer F, Park G, Hamwi I, Palmqvist L, Lai CK, Leung M, Lin G, Chaturvedi A, Thakur BK, Iwasaki M, Bilenky M, Thiessen N, Robertson G, Hirst M, Kent D, Wilson NK, Göttgens B, Eaves C, Cleary ML, Marra M, Ganser A, Humphries RK.

Cancer Cell. 2011 Jul 12;20(1):39-52. doi: 10.1016/j.ccr.2011.06.020.

28.

Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.

Yokoyama A, Ficara F, Murphy MJ, Meisel C, Naresh A, Kitabayashi I, Cleary ML.

J Cell Sci. 2011 Jul 1;124(Pt 13):2208-19. doi: 10.1242/jcs.080523.

29.

TALE homeodomain proteins regulate site-specific terminal differentiation, LCE genes and epidermal barrier.

Jackson B, Brown SJ, Avilion AA, O'Shaughnessy RF, Sully K, Akinduro O, Murphy M, Cleary ML, Byrne C.

J Cell Sci. 2011 May 15;124(Pt 10):1681-90. doi: 10.1242/jcs.077552. Epub 2011 Apr 21.

30.

MicroRNA programs in normal and aberrant stem and progenitor cells.

Arnold CP, Tan R, Zhou B, Yue SB, Schaffert S, Biggs JR, Doyonnas R, Lo MC, Perry JM, Renault VM, Sacco A, Somervaille T, Viatour P, Brunet A, Cleary ML, Li L, Sage J, Zhang DE, Blau HM, Chen C, Chen CZ.

Genome Res. 2011 May;21(5):798-810. doi: 10.1101/gr.111385.110. Epub 2011 Mar 30.

31.

Suggestions for reviewing clinical continuing education courses.

Cleary ML, Walter G.

J Contin Educ Nurs. 2011 Mar;42(3):105-6. doi: 10.3928/00220124-20110222-04.

PMID:
21366197
32.

A novel Gli3 enhancer controls the Gli3 spatiotemporal expression pattern through a TALE homeodomain protein binding site.

Coy S, Caamaño JH, Carvajal J, Cleary ML, Borycki AG.

Mol Cell Biol. 2011 Apr;31(7):1432-43. doi: 10.1128/MCB.00451-10. Epub 2011 Jan 24.

33.

GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.

Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH, Smith KS, Cleary ML.

Cancer Cell. 2010 Jun 15;17(6):597-608. doi: 10.1016/j.ccr.2010.04.024.

34.

Molecular mechanism of MLL PHD3 and RNA recognition by the Cyp33 RRM domain.

Hom RA, Chang PY, Roy S, Musselman CA, Glass KC, Selezneva AI, Gozani O, Ismagilov RF, Cleary ML, Kutateladze TG.

J Mol Biol. 2010 Jul 9;400(2):145-54. doi: 10.1016/j.jmb.2010.04.067. Epub 2010 May 8.

35.

Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Somervaille TC, Cleary ML.

Int J Hematol. 2010 Jun;91(5):735-41. doi: 10.1007/s12185-010-0579-8. Epub 2010 May 8.

PMID:
20454944
36.

Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, Gozani O, Kutateladze TG, Cleary ML.

J Mol Biol. 2010 Jul 9;400(2):137-44. doi: 10.1016/j.jmb.2010.05.005. Epub 2010 May 7.

37.

Giving feedback to learners in clinical and academic settings: practical considerations.

Cleary ML, Walter G.

J Contin Educ Nurs. 2010 Apr;41(4):153-4. doi: 10.3928/00220124-20100326-10.

PMID:
20411885
38.

The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.

Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C, Chen CZ, Cleary ML.

Cancer Res. 2010 May 1;70(9):3833-42. doi: 10.1158/0008-5472.CAN-09-3268. Epub 2010 Apr 20.

39.

Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6.

Liedtke M, Ayton PM, Somervaille TC, Smith KS, Cleary ML.

Blood. 2010 Jul 8;116(1):63-70. doi: 10.1182/blood-2009-09-243386. Epub 2010 Apr 15.

40.

Preview. Mutant CEBPA: Priming Stem Cells for Myeloid Leukemogenesis.

Somervaille TC, Cleary ML.

Cell Stem Cell. 2009 Nov 6;5(5):453-4. doi: 10.1016/j.stem.2009.10.008.

41.

A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML.

Cancer Cell. 2010 Feb 17;17(2):198-212. doi: 10.1016/j.ccr.2009.12.040.

42.

Regulating the leukaemia stem cell.

Cleary ML.

Best Pract Res Clin Haematol. 2009 Dec;22(4):483-7. doi: 10.1016/j.beha.2009.08.005. Review.

43.

Essential role for Pbx1 in corneal morphogenesis.

Murphy MJ, Polok BK, Schorderet DF, Cleary ML.

Invest Ophthalmol Vis Sci. 2010 Feb;51(2):795-803. doi: 10.1167/iovs.08-3327. Epub 2009 Sep 24.

44.

A consideration of contemporary factors influencing professional development in health research.

Cleary ML, Walter G, Horsfall J, Matheson S.

J Contin Educ Nurs. 2009 Jun;40(6):273-9. Review.

PMID:
19639917
45.

Therapeutic targeting of MLL.

Liedtke M, Cleary ML.

Blood. 2009 Jun 11;113(24):6061-8. doi: 10.1182/blood-2008-12-197061. Epub 2009 Mar 16. Review.

46.

Ectopic Meis1 expression in the mouse limb bud alters P-D patterning in a Pbx1-independent manner.

Mercader N, Selleri L, Criado LM, Pallares P, Parras C, Cleary ML, Torres M.

Int J Dev Biol. 2009;53(8-10):1483-94. doi: 10.1387/ijdb.072430nm.

47.

Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells.

Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR, Cleary ML.

Cell Stem Cell. 2009 Feb 6;4(2):129-40. doi: 10.1016/j.stem.2008.11.015.

48.

Pbx1 functions in distinct regulatory networks to pattern the great arteries and cardiac outflow tract.

Chang CP, Stankunas K, Shang C, Kao SC, Twu KY, Cleary ML.

Development. 2008 Nov;135(21):3577-86. doi: 10.1242/dev.022350.

49.

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML.

Nature. 2008 Oct 30;455(7217):1205-9. doi: 10.1038/nature07284. Epub 2008 Sep 17.

50.

Pbx/Meis deficiencies demonstrate multigenetic origins of congenital heart disease.

Stankunas K, Shang C, Twu KY, Kao SC, Jenkins NA, Copeland NG, Sanyal M, Selleri L, Cleary ML, Chang CP.

Circ Res. 2008 Sep 26;103(7):702-9. doi: 10.1161/CIRCRESAHA.108.175489. Epub 2008 Aug 21.

Supplemental Content

Loading ...
Support Center